{"id":"W4313140213","doi":"10.1136/ijgc-2022-esgo.518","title":"2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; University of Alberta; Alberta Health Services; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Combination therapy; CD8; Renal cell carcinoma; Cytokine; Immunotherapy; Gastroenterology; Nivolumab; Oncology; Pharmacology; Phases of clinical research; Cancer research; Immunology; Chemotherapy; Cancer; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005581319,0.0003606497,0.0006423147,0.0002812237,0.000168126,0.0005872359,0.0002454001,0.0004045218,0.003358779],"category_scores_gemma":[0.0004660992,0.0001527242,0.000679062,0.0002238447,0.0001799074,0.0003735922,0.0002028898,0.0008309436,0.0005999136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003875796,"about_ca_system_score_gemma":0.0005051757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004760521,"about_ca_topic_score_gemma":0.001926541,"domain_scores_codex":[0.9997985,0.00008024646,0.00001922478,0.00002575994,0.00003272941,0.000043626],"domain_scores_gemma":[0.9998597,0.00003098576,0.00002117037,0.00001181476,0.00002104046,0.00005516522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1428447,0.006320125,0.03995539,0.001954476,0.003477161,0.001237039,0.0002027647,0.001831619,0.03551966,0.0009770303,0.01630931,0.7493706],"study_design_scores_gemma":[0.09693348,0.2028923,0.4254107,0.001534707,0.006918511,0.007612499,0.0007685405,0.01003024,0.01924467,0.00184214,0.2265957,0.0002164106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.903138,0.06888717,0.0005699673,0.002516505,0.0009708425,0.0003594686,0.0008771642,0.0001018369,0.02257903],"genre_scores_gemma":[0.9798069,0.0120267,0.0009562797,0.001090624,0.0003952635,0.0001398871,0.001067037,0.000009955491,0.00450732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003358779,"threshold_uncertainty_score":0.01123625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007700267472341213,"score_gpt":0.2772337533473079,"score_spread":0.2695334858749667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}